×
0 0 0 0 0 0 0 0
Stockreport

Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results

ATHENEX (ATNX)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: ir.athenex.com
PDF Fourth Quarter 2017 and Recent Business Highlights: Met enrollment targets and received positive feedback from the US FDA for Oraxol Phase III Clinical Trial in metastatic breast cancerAnnounced strategic partnership with Almirall for KX2-391 Ointment for the treatment of actinic keratosisReceived a Promising Innovative Medicine (PIM) designation for Oraxol by the UK Medicines and Healthcare Products Regulatory AgencyCompleted patient enrollment for both Phase III clinical studies of KX2-391 Ointment for actinic keratosis indications months ahead of scheduleLaunched 7 new products, including Epinephrine, Norepinephrine, Caspofungin Acetate Injection, Doxorubicin, Etomidate Injection, Gemcitabine Injection and Paclitaxel Injection in the Athenex Pharmaceutical Division, further expanding the APD product portfolioAnnounced secondary stock offering raising approximately $68 million in capitalRevenue of $14.9 million for the fourth quarter 2017, up $9.7 million year-over-yearFull-year re [Read more]

IMPACT SNAPSHOT EVENT TIME: ATNX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ATNX alerts
from News Quantified
Opt-in for
ATNX alerts

from News Quantified
Opt-in for
ATNX alerts

from News Quantified